Clinical Trials Logo

Clinical Trial Summary

ActiCIDP is a monocentric academic study. Patients with Chronic inflammatory demyelinating polyradiculoneuritis may be included on a voluntary basis. The investigators plan to include a group of approximately 40 patients with CIDP. The investigators have planned to assess patient every three months for a year. After each visit, participants will wear Actimyo for one month daily.


Clinical Trial Description

On each visit, participants will undergo a clinical examination with MRC sum score, a mISS score and a I-RODS score. They will perform few tests 6-minutes walk test (6MWT), a myogrip measurement, and a 9 Hole Peg Test (9HPT) and will answer to some questionaires (mISS, INCAT and PGIC). Actimyo is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle. ;


Study Design


Related Conditions & MeSH terms

  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Polyneuropathies
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT number NCT06183645
Study type Observational
Source Centre Hospitalier Universitaire de Liege
Contact Laura Buscemi
Phone 043215584
Email laura.buscemi@citadelle.be
Status Recruiting
Phase
Start date August 28, 2023
Completion date January 2028

See also
  Status Clinical Trial Phase
Completed NCT02465359 - Subcutaneous Immunoglobulin for CIDP N/A
Recruiting NCT05584631 - IVIG vs SCIG in CIDP Phase 1
Withdrawn NCT01236456 - High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Phase 2
Terminated NCT03779828 - Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP
Completed NCT01184846 - Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Phase 3
Recruiting NCT05011006 - NT-3 Levels and Function in Individuals With CMT
Recruiting NCT06290141 - A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Phase 3
Completed NCT01379833 - Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Completed NCT02414490 - IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements
Completed NCT01545076 - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Phase 3
Active, not recruiting NCT00716066 - Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases Phase 2
Recruiting NCT04672733 - Hizentra® in Inflammatory Neuropathies - pHeNIx Study
Not yet recruiting NCT04480450 - Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy Phase 2
Completed NCT01931644 - At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Not yet recruiting NCT05219383 - Clinical and Electrophysiological Patterns of Chronic Dysimmune Polyneuropathy
Completed NCT02111590 - Immunoglobulin Dosage and Administration Form in CIDP and MMN N/A
Recruiting NCT04292834 - A Registered Cohort Study of Immune-Mediated Neuropathies
Terminated NCT03772717 - Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) N/A
Completed NCT00278629 - Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Phase 2
Recruiting NCT02372149 - IVIg for Demyelination in Diabetes Mellitus Phase 4